Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Chlorphenesin Carbamate with mFOLFIRINOX in Pancreatic Cancer
NCT05083780Phase 1Active, not recruiting
- Start
- Nov 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of chlorphenesin carbamate and hydroxychloroquine in pancreatic cancer (PC). Primary endpoint: Number of participants with treatment-related adverse events assessed by CTCAE v5.0 up to 3 years. Started Nov 2021; status: active, not recruiting.
02
Drugs
chlorphenesin carbamatehydroxychloroquine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05083780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083780.